Stryker Corporation

Stryker Corporation (SYK) Market Cap

Stryker Corporation has a market capitalization of $131.38B.

Financials based on reported quarter end 2025-12-31

Price: $343.32

β–² 4.94 (1.46%)

Market Cap: 131.38B

NYSE Β· time unavailable

CEO: Kevin A. Lobo

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 1980-03-17

Website: https://www.stryker.com

Stryker Corporation (SYK) - Company Information

Market Cap: 131.38B Β· Sector: Healthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Analyst Sentiment

79%
Strong Buy

Based on 29 ratings

Analyst 1Y Forecast: $423.76

Average target (based on 5 sources)

Consensus Price Target

Low

$390

Median

$427

High

$469

Average

$429

Potential Upside: 24.9%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Stryker Corporation (SYK) β€” Investment Overview

🧩 Business Model Overview

Stryker Corporation is a global leader in medical technologies with a comprehensive portfolio spanning orthopaedics, medical and surgical equipment, neurotechnology, and spine. The company serves a broad customer base including hospitals, ambulatory surgery centers, clinics, and healthcare systems worldwide. Its operations cover the design, manufacture, and distribution of a wide array of products such as implants for joint replacement, surgical navigation systems, patient handling equipment, surgical instruments, neurovascular devices, and specialized hospital beds. Stryker’s presence is diversified across developed and emerging markets, with substantial investments in research and development enabling a steady pace of innovative new product introductions.

πŸ’° Revenue Model & Ecosystem

Stryker generates revenue through a multifaceted model that blends durable medical device sales with recurring income streams from consumables, disposables, maintenance contracts, and software-enabled services. Large capital equipment sales, such as surgical robots and advanced imaging systems, foster subsequent recurring revenues via consumables, instrument sets, and service agreements throughout the product lifecycle. The company also offers digital and data-driven solutions, supporting enterprise-level hospital customers with workflow optimization, operating room integration, and asset tracking software. This combination of hardware, procedural consumables, and service solutions cultivates long-term customer relationships and underpins predictable revenue streams.

🧠 Competitive Advantages

  • Brand strength: Stryker’s legacy, clinically validated products, and broad distribution footprint underpin a widely trusted reputation among clinicians and administrators.
  • Switching costs: Hospitals and surgeons are deeply invested in Stryker’s device platforms, with training, procedural workflow, and inventory tailored to Stryker solutions, making transitions costly and disruptive.
  • Ecosystem stickiness: Integrated hardware and software platforms, proprietary consumables, and embedded service contracts drive customer loyalty and recurring touchpoints.
  • Scale + supply chain leverage: Stryker’s global manufacturing, R&D, and distribution scale support cost efficiencies and rapid innovation cycles, while ensuring resilience in sourcing and fulfillment.

πŸš€ Growth Drivers Ahead

Stryker’s growth prospects are underpinned by several secular and strategic themes. Rising global demand for orthopedic proceduresβ€”driven by aging populations and increasing chronic disease prevalenceβ€”continues to expand the addressable market for implants and surgical technologies. The adoption of robotic-assisted surgery and advanced digital operating room integration positions Stryker as a leader in next-generation procedural innovation. Expanding access and adoption in emerging markets provides a further channel for long-term revenue growth. Additionally, ongoing portfolio expansion via targeted acquisitions and internal R&D investments strengthen Stryker’s category leadership across new clinical adjacencies and procedural areas.

⚠ Risk Factors to Monitor

Key risks include intensifying competition from both large diversified medtech companies and upstart innovators, particularly in rapidly evolving areas like orthopaedic robotics and minimally invasive surgery. Regulatory scrutiny and policy shifts in healthcare reimbursement can impact product launches, pricing power, and margin structures. Input cost fluctuations, supply chain disruptions, and integration challenges from M&A activity may also exert pressure. Furthermore, the pace of technological change presents the risk of displacement if Stryker’s innovation pipeline lags those of competitors or if disruptive new entrants alter the competitive landscape.

πŸ“Š Valuation Perspective

Stryker is typically valued by the market at a meaningful premium relative to most industry peers, reflecting its proven track record of consistent growth, diversified product portfolio, and high recurring revenue mix. This premium is anchored by investor expectations for steady margin expansion, robust innovation, and strong execution in key medtech verticals. Conversely, valuation tends to be sensitive to changes in competitive positioning, regulatory risk, or signs of decelerating organic growth.

πŸ” Investment Takeaway

Stryker presents an appealing case for investors seeking exposure to the defensive, innovation-driven healthcare sector. Its strong brand, recurring revenue streams, and scalable global platform underpin resilience and adaptability amid industry shifts. The principal challenges lie in sustaining innovation, navigating complex regulatory settings, and defending market share in an increasingly technological and competitive field. Success will depend on management’s continued ability to execute on integration, portfolio expansion, and R&D excellence. Overall, Stryker balances significant long-term opportunity against the inherent risks of a dynamic, high-stakes medtech landscape.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Stryker Corporation (SYK) reported Q4 revenue of $7.171 billion with a net income of $849 million, resulting in an EPS of $2.21. The net margin stands at approximately 11.8%, and the company generated a significant free cash flow of $1.875 billion. Over the past year, the revenue grew modestly, indicating stable performance in its operational execution. Stryker maintains a strong profitability profile with a net margin of 11.8%, reflecting effective cost management and operational efficiency. Cash flow quality remains robust with an operating cash flow of $2.143 billion and FCF of $1.875 billion, bolstered by disciplined capital expenditures. The balance sheet shows a net debt of $10.848 billion, which underlines moderate leverage given its assets of $47.844 billion. Shareholder returns include dividends totaling $3.40 per share annually, indicative of a shareholder-friendly approach. Analyst sentiment reflects a consensus price target of $425.58, suggesting potential stock performance alignment with market expectations."

Revenue Growth

Positive

Revenue saw modest growth, driven largely by core operations stability. The company maintains strong sales channels.

Profitability

Good

Net margin at 11.8% highlights solid profitability. EPS has been stable, indicative of consistent operational efficiency.

Cash Flow Quality

Strong

Strong FCF at $1.875 billion and reliable dividend payments reflect high cash flow quality and liquidity.

Leverage & Balance Sheet

Positive

Moderate net debt relative to total equity. Financial structure appears stable, supporting future obligations.

Shareholder Returns

Good

Dividends per share at $3.40 for the year illustrate solid returns and commitment to rewarding shareholders.

Analyst Sentiment & Valuation

Good

Analyst consensus indicates a positive outlook with a median target of $419, suggesting confidence in valuation alignment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Stryker delivered a strong Q4 and FY 2025 with double-digit organic growth, record Mako installations, margin expansion, and robust cash flow. Capital demand and procedural volumes remained healthy, supporting 2026 guidance above market with 8–9.5% organic growth and higher EPS. Management highlighted structural growth drivers, continued pricing discipline, and strong international opportunities. While tariffs, interest expense, and certain competitive pockets pose headwinds, the overall tone and outlook are confident and growth-focused.

Growth

  • Q4 organic sales +11%; FY 2025 organic sales +10.3% (vs +10.2% in 2024)
  • FY U.S. organic sales +11.2%; FY international organic sales +7.5% (strength in emerging markets, South Korea, Japan)
  • Q4 MedSurg & Neurotechnology organic sales +12.6% (U.S. +13%; international +10.9%)
  • Q4 Orthopaedics organic sales +8.4% (U.S. +9.6%; international +5.4%)
  • U.S. Knee +7.6%; U.S. Hips +5.6%; U.S. Trauma & Extremities +8.5%; U.S. Other Ortho +28.7% (Mako 4 installations)
  • U.S. Instruments +19.1% (high-teens growth in orthopedic instruments and Surgical Technologies)
  • U.S. Endoscopy +11.1% (double-digit in sustainability and sports medicine; core endoscopy high single digit)
  • U.S. Medical +13.6% (driven by 35, Procuity, Oceara, and Sage)
  • U.S. Vascular +4.3% (double-digit hemorrhagic growth from Surpass Elite; ischemic competitive pressure)
  • U.S. Neurocranial +9.9%
  • Q4 pricing slightly favorable; Q4 FX +1% to sales; FY pricing +0.4%; FY FX +0.5% to sales

Business Development

  • Formed SmartCare business unit combining Vocera and Care AI
  • Split multiple sales forces; launched new breast care sales force within Endoscopy in 2025
  • Inari rebranded as Peripheral business within Vascular; high-teens procedural growth, with destocking (minimal in Q1 2026)
  • Record Mako 4 installations; installed base >3,000 globally; new applications include advanced primary with revision hip and spine; shoulder to launch on Mako 4 mid-2026
  • Key product highlights: Surpass Elite flow-diverting stent, 1788 video platform, Insignia HipStem, Pangaea plating, SteraShield, Neptune waste management, smoke evacuation, Procuity, Oceara, Sage

Financials

  • Q4 adjusted EPS $4.47 (+11.5% YoY); FY adjusted EPS $13.63 (+11.8% YoY)
  • Q4 adjusted gross margin 65.2% (-10 bps YoY) reflecting tariffs, offset by mix and cost improvements
  • Q4 adjusted operating margin 30.2% (+100 bps YoY); second consecutive year of β‰₯100 bps adjusted operating margin expansion (return to pre-COVID levels)
  • Cash from operations $5.0B in 2025 (up $820M YoY); FCF = 81% of adjusted net earnings (vs 75% in 2024); target 70–80%
  • Q4 adjusted other income/expense $(107)M (higher by $56M YoY) due to increased interest expense and lower interest income; FY 2026 OI&E expected β‰ˆ $420M
  • Q4 adjusted effective tax rate 16.1%; FY 2026 expected tax rate 15%–16%
  • FX translation impact: Q4 $(0.02) to EPS; FY +$0.01 to EPS

Capital & Funding

  • Hospital CapEx budgets remain healthy; capital order book elevated entering 2026
  • Robust capital performance in Instruments, Medical, and Endoscopy; record Mako installations in Q4 and FY
  • Financial position strong, providing firepower for M&A in 2026
  • Higher interest expense from debt issuances earlier in 2025

Operations & Strategy

  • Operational excellence focus driving margin expansion; ongoing supply chain and manufacturing optimization
  • Pricing discipline expected to remain similar to 2025
  • Structural growth pillars: talent/culture, active M&A, steady product launch cadence, and specialization via new business units and sales force splits
  • Leadership in U.S. knees and hips; rising Mako utilization (U.S.: >2/3 of knees and >1/3 of hips; global: ~50% knees, >20% hips)
  • Do not expect 2025 supply constraints in Medical to negatively impact 2026 growth
  • Exiting certain international spinal implant markets after fulfilling accepted tenders
  • Leadership changes: Spencer Stiles named President & COO; Dylan Crotty to lead Orthopaedics

Market & Outlook

  • Procedural volumes remained healthy in Q4; markets expected to stay strong in 2026
  • Drivers include adoption of robotic-assisted surgery, favorable demographics, and durable capital demand
  • Geographic outlook: robust demand in emerging markets, South Korea, Japan, Australia/New Zealand; slower capital environment in Europe
  • 2026 guidance: organic net sales growth 8.0%–9.5%; adjusted EPS $14.90–$15.10
  • 2026 assumptions: modestly positive pricing; slight FX tailwind; same selling days as 2025; seasonality similar

Risks Or Headwinds

  • Tariffs remain a significant headwind; FY 2026 impact β‰ˆ $400M (including ~$200M incremental vs 2025, realized in H1)
  • Higher interest expense and lower interest income elevate non-operating costs
  • Competitive pressures in ischemic vascular business
  • Peripheral business experienced destocking (expected minimal in Q1 2026)
  • Slower capital environment in Europe
  • Ability to sustain ~10% growth depends on macro environment and procedure trends
  • FX volatility

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the SYK Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (SYK)

Β© 2026 Stock Market Info β€” Stryker Corporation (SYK) Financial Profile
Stryker Corporation (SYK) Market Cap, Stock Analysis & Valuation